SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories - Quaterly Results

14 Feb 2022 Evaluate
The quarter ended December 2021 witnessed marginal change in the total revenue. The figure for the mentioned quarter is pegged at Rs. 13284.70 millions.A slender decline of -16.08% was recorded to Rs. 2181.70  millions from Rs. 2599.70 millions in the corresponding previous quarter.A decline of 3247.60 millions was observed in the OP in the quarter ended December 2021 from 3644.80 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 13284.70 13152.20 1.01 42309.10 40982.40 3.24 51391.60 43674.30 17.67
Other Income 132.40 156.50 -15.40 419.20 423.30 -0.97 622.40 646.90 -3.79
PBIDT 3247.60 3644.80 -10.90 11064.40 13392.70 -17.38 15758.20 9794.50 60.89
Interest 12.70 15.60 -18.59 40.00 58.30 -31.39 81.40 157.90 -48.45
PBDT 3234.90 3629.20 -10.86 11024.40 13334.40 -17.32 15676.80 9636.60 62.68
Depreciation 512.50 476.60 7.53 1517.10 1391.50 9.03 1877.20 1786.90 5.05
PBT 2722.40 3152.60 -13.65 9507.30 11942.90 -20.39 13799.60 7849.70 75.80
TAX 540.70 552.90 -2.21 1902.00 2050.00 -7.22 2391.90 1325.10 80.51
Deferred Tax 64.50 1.90 3294.74 239.00 -37.00 -745.95 -57.90 -54.70 5.85
PAT 2181.70 2599.70 -16.08 7605.30 9892.90 -23.12 11407.70 6524.60 74.84
Equity 253.70 253.70 0.00 253.70 253.70 0.00 253.70 252.70 0.40
PBIDTM(%) 24.45 27.71 -11.79 26.15 32.68 -19.98 30.66 22.43 36.73

Ipca Laboratories Share Price

1551.75 -6.15 (-0.39%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×